D Huber1, S Seitz1, K Kast2, G Emons3, O Ortmann4. 1. Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany. 2. Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. 3. Department of Gynecology and Obstetrics, Georg August University Göttingen, University Medicine, Göttingen, Germany. 4. Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany. olaf.ortmann@klinik.uni-regensburg.de.
Abstract
PURPOSE: BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Oral contraception (OC) is known to increase breast cancer and reduce ovarian cancer risk in the general population. This review analyses the published data on OC and risk of cancer in BRCA mutation carriers. METHODS: We included all relevant articles published in English from 1995 to 2018. Literature was identified through a search on PubMed and Cochrane Library. RESULTS: We included four meta-analyses, one review, one case-control study and one retrospective cohort study on the association between ovarian cancer and OC in BRCA mutation carriers. All report a risk reduction for the OC users and several also describe an inverse correlation with duration of use. Regarding breast cancer, we included four meta-analyses, one review, one case-control study, two case-only studies, one prospective and one retrospective cohort study. Some studies report a risk elevation, while others did not find an association between OC use and breast cancer in BRCA mutation carriers. In other studies, the association was limited to early-onset breast cancer and/or associated with young age at first start of OC. CONCLUSION: Oral contraception leads to a risk reduction of ovarian cancer also in BRCA mutation carriers. An increase in breast cancer risk due to OC cannot be excluded. Women with BRCA mutation who consider OC use have to be informed about possible increase in breast cancer risk and alternative contraceptive methods. OC should not be used for the prevention of ovarian cancer in this population.
PURPOSE:BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Oral contraception (OC) is known to increase breast cancer and reduce ovarian cancer risk in the general population. This review analyses the published data on OC and risk of cancer in BRCA mutation carriers. METHODS: We included all relevant articles published in English from 1995 to 2018. Literature was identified through a search on PubMed and Cochrane Library. RESULTS: We included four meta-analyses, one review, one case-control study and one retrospective cohort study on the association between ovarian cancer and OC in BRCA mutation carriers. All report a risk reduction for the OC users and several also describe an inverse correlation with duration of use. Regarding breast cancer, we included four meta-analyses, one review, one case-control study, two case-only studies, one prospective and one retrospective cohort study. Some studies report a risk elevation, while others did not find an association between OC use and breast cancer in BRCA mutation carriers. In other studies, the association was limited to early-onset breast cancer and/or associated with young age at first start of OC. CONCLUSION: Oral contraception leads to a risk reduction of ovarian cancer also in BRCA mutation carriers. An increase in breast cancer risk due to OC cannot be excluded. Women with BRCA mutation who consider OC use have to be informed about possible increase in breast cancer risk and alternative contraceptive methods. OC should not be used for the prevention of ovarian cancer in this population.
Entities:
Keywords:
BRCA1; BRCA2; Breast cancer; Oral contraception; Ovarian cancer
Authors: S Iodice; M Barile; N Rotmensz; I Feroce; B Bonanni; P Radice; L Bernard; P Maisonneuve; S Gandini Journal: Eur J Cancer Date: 2010-05-27 Impact factor: 9.162
Authors: I B Runnebaum; S Wang-Gohrke; D Vesprini; R Kreienberg; H Lynch; R Moslehi; P Ghadirian; B Weber; A K Godwin; H Risch; J Garber; C Lerman; O I Olopade; W D Foulkes; B Karlan; E Warner; B Rosen; T Rebbeck; P Tonin; M P Dubé; D G Kieback; S A Narod Journal: Pharmacogenetics Date: 2001-10
Authors: Antonis C Antoniou; Matti Rookus; Nadine Andrieu; Richard Brohet; Jenny Chang-Claude; Susan Peock; Margaret Cook; D Gareth Evans; Rosalind Eeles; Catherine Nogues; Laurence Faivre; Paul Gesta; Flora E van Leeuwen; Margreet G E M Ausems; Ana Osorio; Trinidad Caldes; Jacques Simard; Jan Lubinski; Anne-Marie Gerdes; Edith Olah; Christine Fürhauser; Hakan Olsson; Brita Arver; Paolo Radice; Douglas F Easton; David E Goldgar Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-03 Impact factor: 4.254
Authors: John R McLaughlin; Harvey A Risch; Jan Lubinski; Pal Moller; Parviz Ghadirian; Henry Lynch; Beth Karlan; David Fishman; Barry Rosen; Susan L Neuhausen; Kenneth Offit; Noah Kauff; Susan Domchek; Nadine Tung; Eitan Friedman; William Foulkes; Ping Sun; Steven A Narod Journal: Lancet Oncol Date: 2007-01 Impact factor: 41.316
Authors: S A Narod; H Risch; R Moslehi; A Dørum; S Neuhausen; H Olsson; D Provencher; P Radice; G Evans; S Bishop; J S Brunet; B A Ponder Journal: N Engl J Med Date: 1998-08-13 Impact factor: 91.245
Authors: Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson Journal: JAMA Date: 2017-06-20 Impact factor: 56.272
Authors: A S Whittemore; R R Balise; P D P Pharoah; R A Dicioccio; I Oakley-Girvan; S J Ramus; M Daly; M B Usinowicz; K Garlinghouse-Jones; B A J Ponder; S Buys; R Senie; I Andrulis; E John; J L Hopper; M S Piver Journal: Br J Cancer Date: 2004-11-29 Impact factor: 7.640
Authors: Antonio El Kareh; Steven Safi; Théa Kaady; Said El Hage; Elie Mokled; Elise Assouad; Elie Snaifer; Reine Nader Journal: Ecancermedicalscience Date: 2022-06-13
Authors: Lieske H Schrijver; Thea M Mooij; Anouk Pijpe; Gabe S Sonke; Marian J E Mourits; Nadine Andrieu; Antonis C Antoniou; Douglas F Easton; Christoph Engel; David Goldgar; Esther M John; Karin Kast; Roger L Milne; Håkan Olsson; Kelly-Anne Phillips; Mary Beth Terry; John L Hopper; Flora E van Leeuwen; Matti A Rookus Journal: J Natl Cancer Inst Date: 2022-04-11 Impact factor: 13.506